

October 29, 2026

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS
--	--

Dear Sir / Madam,

Sub: **Investors / Analysts Presentation**

Please find enclosed the presentation to the Investors / Analysts on the Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, for the Investors / Analysts call scheduled on October 29, 2026 at 05.00 p.m. (IST), which was already intimated on October 13, 2026.

The presentation is also being uploaded on the website of the Company i.e., www.lauruslabs.com.

This is for your information and records.

Thanking you.

Yours sincerely,

For **Laurus Labs Limited**

VANTARAM

VENKATA RAVI

KUMAR

V V Ravi Kumar

Executive Director and CFO

DIN: 01424180

Digitally signed by
VANTARAM VENKATA
RAVI KUMAR
Date: 2026.10.29
15:16:38 +05'30'

Encl: A/a

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Q2 & H1-FY 2027 Financial Results

29/10/2026



Safe Harbor Statement

This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise.

This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same.

Agenda

- 1 Q2 & H1 - FY 2027 Corporate Overview
- 2 Q2 & H1 - FY 2027 Financial Overview
- 3 Q2 & H1 - FY 2027 Business Review & Strategy

1

Corporate Overview

Q2 & H1 FY 2027



Executive Summary

- Strong H1 performance ; ₹ 4,233 Cr Revenue with 31% growth
- Sustained strong growth in CDMO revenue driven by commercial supplies and steady momentum in Affordable Medicines division
- ₹ 1,406 Cr EBITDA with margins of 33.2%, increased by 7.8% pts, contributed by higher CDMO revenue and operational leverage
- Gross margins expansion of over 3.3% pts to 62.9% on healthy business segment mix
- Announced investments in two technology platforms to strengthen Integrated CDMO offering; Oligonucleotides and peptide-resins
- CAPEX/Revenue reached 20%, reflecting sustained investment in expanding the manufacturing network and niche capabilities



Strengthen CDMO expertise – Proposed Acquisition Overview



Montreal, Canada



Expanding CDMO offering in high growth Oligonucleotide modality

- Definitive agreement to acquire 60% stake in Galenvs, specialized in Oligonucleotide and Precision Magnetic Nanoparticles for purification
- Expands Laurus position in fast growing Oligo market (+22-24% CAGR) with a North American development footprint
- Galenvs early-stage Oligo platform + Laurus large-scale expertise in complex chemistry allows to deliver Integrated service for complex RNA/DNA based therapies
- Plans to expand scientific talent in Montreal and manufacturing infrastructure in India

Market size

~\$ 11 bn+
2030

+22-24% CAGR

Galenvs capabilities

Antisense, Aptamers
siRNA
sgRNA
Advance purification
incl fill finish
Pilot-scale synthesis



Hyderabad, India




Enhance Supply chain security and Peptides manufacturing competitiveness

- Proposed to acquire 52% stake in SI & C Resins, a peptide-resin technology focused company
- Expertise with >15 year experience in peptide/polymer chemistry
- Ability to develop and manufacture, peptide solid support resins and chromatography stationary phases
- Enhanced manufacturing competitiveness and Reliability
- Rapid expansion in GLP-1 and non-GLP-1 peptide drugs

Investments aligns with Laurus strategy to strengthen Integrated scientific capabilities & manufacturing infrastructure


Laurus Peptide CDMO platform and focus on continued capacity expansion



Advancing end-to-end Peptide capabilities – Resins, amino acid derivatives, SPPS/LPPS/Purification/Isolation

Advancing Key CAPEX projects across portfolio and technologies

- >85% of Growth CAPEX planned into diversified portfolio with high-growth projects in API, Formulations, Peptides, Fermentation, Gene Therapy and ADCs
- Healthy order book, strong internal pipeline, and key customer commitments
- H1 CAPEX at ₹ 864 Cr; 20% of Revenue
- ATR improving in medium-term in-line with 6 year Long term average




* Cumulative addition including CWIP, Land, ETP and plant maintenance till September 2026

Laurus intends to invest > ₹ 3,000 Cr over FY27 and FY28 across Manufacturing network and Capability expansion

Key Growth investment projects – Enhancing broadest capability offering

1

Large-scale Peptides API manufacturing



- SPPS, LPPS and hybrid approaches + advanced downstream technology
- Large scale capacity for GLP & non-GLP programs

2

Large-scale API facility Unit -7



- Multiple API blocks, Flexible manufacturing
- Large-scale API capacity
- Future expansion

3

Enzyme Fermentation plant boosting biocatalysis capacity



- Commercial scale manufacturing and Future expansion scope (>1.2mn liters)
- Precision fermentation and strain engineering


4

Commercial Gene & ADC platform with fill-finish



- One-stop Service platform for complete ADC programs (Payload-linker, Conjugation, Fill-finish)
- Commercial-scale capacity

Strengthening Development & Manufacturing Capabilities to meet Customer demand



Consistent ESG recognition and Advancing initiatives against SBTi targets

SBTi roadmap towards GHG reduction target 2031

Scope 1 + 2

Target

-42%

Absolute reduction by 42% until FY31 (vs. FY25)

Scope 3

Target

-51.6%

Intensity reduction per ₹ by 51.6% until FY31 (vs. FY25)



SCIENCE
BASED
TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

- Investments >50% electricity from renewable source (Wind+Solar) by 2031 via PPA for all sites
- Making progress on SBTi near term GHG emission targets
- Sustainable Procurement code inline with ISO 20400:2017 principles established

Key recognitions for our ESG programs



Laurus Labs Limited
Pharmaceuticals

**Sustainability
Yearbook Member**

Corporate Sustainability
Assessment (CSA) 2025

MSCI
ESG RATINGS

BBB

CCC B BB BBB A AA AAA

S&P Global ESG Score

81/100

Data Availability: Very High

Last updated: November 05, 2025



NATIONAL SAFETY COUNCIL OF INDIA
SAFETY AWARDS



UN GLOBAL COMPACT

Great Place To Work
Certified
JUL 2025-JUL 2026
INDIA

CareEdge
ESG RATINGS
A subsidiary of CARE Ratings Limited

**SCORE
82.6**

© 2026 Laurus Labs Ltd.

Q2 & H1 - FY27 Results Presentation

29/10/2026

11



LAURUS Labs
Chemistry for Better Living

2

Financial Overview

Q2 & H1 FY 2027



1H FY27: Sustained strong performance

1H FY27 Financial Summary

[₹ Crore]	1H FY27	1H FY26	Y-o-Y
Revenue	4,233	3,223	31%
Gross Margins	62.9%	59.6%	3.3%
EBITDA	1,406	818	72%
% to Revenue	33.2%	25.4%	7.8%
Net Profit	809	358	126%
% to Revenue	19.1%	11.1%	8.0%
EPS (₹)	15.0	6.6	127%
Operating Cash flow	805	1,093	-26%
Capex	864	489	77%
Net Debt-to-EBITDA	1.0x	1.3x	-23%
ROCE	22.5%	16.3%	+6.2%

Comments

- Revenue : ₹ 4,233 Cr, increased 31% driven by CDMO momentum and healthy growth in Affordable Medicines business
- Gross Margins : 62.9%, increased by 330 bps on better divisional mix
- R & D spends reported at ₹ 183 Cr* (4.3% of Revenue), increased by 34% due to development efforts toward building Advanced Biologics infrastructure
- EBITDA : ₹ 1,406 Cr, increased by 72%
- EBITDA Margins : 33.2%, increased 780 bps, due to stronger Revenue growth, higher CDMO revenue and operational leverage
- Net Profits : ₹ 809 Cr, increased 126%
- OCF driven by higher NWC due to increase of strategic Inventories to ensure supply continuity
- Net Debt to EBITDA reduction largely inline
- Strong earning growth driving ROCE despite CAPEX acceleration

* Including Capex R&D spends of ₹ 35 Cr towards Advanced Biologics (Gene therapy and ADC)


1H FY27: Accelerating CDMO execution, supported by AM growth

1H FY27 Divisional Revenue Performance

[₹ Crore]	1H FY27	1H FY26	Y-o-Y
CDMO	1,774	1,040	71%
Small molecules	1,710	964	77%
Bio	64	76	-16%
Affordable Medicines (AM)	2,459	2,183	13%
API	1,280	1,254	2%
FDF	1,179	929	27%
Total Revenue	4,233	3,223	31%
ARV Revenue*	1,404	1,380	2%

* Includes API and Formulation (FDF) combined revenue

1H FY27 Divisional Mix



2Q FY27: Maintaining record momentum across Revenue, EBITDA and Profits

2Q FY27 Financial Summary

[₹ Crore]	1Q FY27	2Q FY27	2Q FY26	Y-o-Y	Q-o-Q
Revenue	2,026	2,206	1,653	33%	9%
Gross Margins	62.7%	63.0%	59.9%	+3.1%	+0.3%
EBITDA	644	762	429	78%	18%
% to Revenue	31.8%	34.5%	26.0%	+8.5%	+2.7%
Net Profit	368	441	195	+126%	+20%
% to Revenue	18.2%	20.0%	11.8%	+8.2%	+1.8%
EPS (₹)	6.8	8.2	3.6	+128%	+21%

Comments

- Revenue : ₹ 2,206 Cr, increased 33% primarily driven by robust CDMO growth supported by sustained Affordable Medicine business (led by FDF)
- Gross Margins : 63.0%, increased by 310 bps on better divisional mix
- R & D spends reported at ₹ 65 Cr (2.9% of Revenue), decreased by 6%
- EBITDA : ₹ 762 Cr, increased by 78% Y/Y
- EBITDA Margins : 34.5%, increased 850 bps Y/Y, due to favorable product mix and improving operational leverage
- Net Profit : ₹ 441 Cr, increased 126% Y/Y


2Q FY27: Driven by Solid CDMO performance

2Q FY27 Divisional Revenue Performance

[₹ Crore]	1Q FY27	2Q FY27	2Q FY26	Y-o-Y	Q-o-Q
CDMO	870	904	518	75%	4%
Small molecules	835	875	471	86%	5%
Bio	35	29	47	-38%	-17%
Affordable Medicines (AM)	1,156	1,302	1,135	15%	13%
API	654	625	617	1%	-4%
FDF	502	677	518	31%	35%
Total Revenue	2,026	2,206	1,653	33%	9%
ARV Revenue*	669	735	733	0.3%	10%


* Includes API and Formulation (FDF) combined revenue

2Q FY27 Divisional Mix




Quarterly Performance Summary: Sustained growth momentum


Revenue




RoCE (ttm EBIT/Capital Employed)



EBITDA & Gross Profit Margins



Net Leverage (Net Debt/ ttM EBITDA)



3

Business Review & Strategy

Q2 & H1 FY 2027




CDMO – Small molecules: Continuous growth and Accelerating capacities

Revenue Growth

[₹ Cr]

Y-o-Y ▲ 86%

Q-o-Q ▲ 5%



Comments

- Robust business model driving rapid growth; H1 increased +77%, anchored by advancing late-stage clinical projects, commercial API supplies and ramp-up of new assets
- **Accelerating Capacity:** Inaugurated Peptide manufacturing facility ahead of schedule; Total SPPS capacity >16,000L and further expanding to service customer needs. Additionally, multiple large-scale API capacity construction in Vizag ongoing
- Elevating client collaboration on complex/new modalities and fully integrated projects (Pre-clinical DS to commercial Drug Product manufacturing)
- CDMO Pipeline continue to expand on high quality molecules and active projects spread across multiple technologies and by indications


Bio – Underlying pipeline progress remain strong

Revenue Growth

[₹ Cr]

Y-o-Y ▼ 38%

Q-o-Q ▼ 17%




Comments

- Y/Y variation is due to campaign phasing; however, underlying pipeline momentum remain strong
- Increasing longer term strategic relationships with major customers across AOF/CDMO to anchor capacity utilization
- Scaling enzymatic technology application across clinical and commercial API projects as part of integrated offering
- LB-4 Fermentation manufacturing unit progressing as planned (>400kL) and set to be commissioned by 3QFY27. Advancing on capacity reservations by customers

Affordable Medicines – Steady progress

Revenue Growth



Global FDF filings	US	EU	Canada	ROW
Approved	39*	19	16	59
Pending	12	3	7	10
Total	51	22	23	69

* Includes 15 Tentative approvals in US

Comments

- Over 13% growth, underpin by continued order uptick, consistent volume and pricing resilience across broader ARV and US portfolio
- Continued resourcing in line with market needs. Potential new launches/integrated CMO engagements and ramping product registration across EM driving healthy outlook
- Sustaining reliable delivery execution amidst global volatility
- KRKA JV update: FDF site progress on track. Phase-I production blocks to be opened in mid-2027 focusing on High Potent and General OSD capability
- Filings update: DMF filings - Cumulatively, 92 filed till date. Developed market FDF filings - 2 dossiers filed and 2 approvals received in H1. Cumulatively, 96 products filed till date

Advanced Biologics – Key Updates



Gene Therapy & Anti body Drug Conjugates (ADCs)

- Commissioning and operational readiness of GMP manufacturing facility on track with focus on integrated offering (PD, Conjugation and Fill-finish capabilities)
- Expanding CDMO opportunities for future growth
- Technology transfer of the acquired ADC programs from Aarvik Therapeutics progressing as planned
- Gram-to-Multi-Kg scale to support clinical/commercial supplies



Cell Therapy

- Continued progress >750 infusions as on Sep 2026
- Gradual ramp-up of the 2nd GMP facility released in March 2026 (capacity to produce +2,500 treatment)
- BCMA Ph-1 trails concluded and initiated Ph-2 studies

Priorities

- ✓ NexCar19 commercial acceleration
- ✓ Expanding Portfolio pipeline
- ✓ Global partnerships & Licensing upside

Highest standard of Quality & Compliance – Commitment to “One Quality for all Markets”

54 Successful Inspections by major Regulators (US FDA, WHO, EU EMA, and Japan PMDA)

1460+ Quality audits & Inspection by Global Customers, Regulators since inception

H1 FY27 update

- 59 Quality audit in H1: Regulatory # 1 & Customer # 58
- On-going improvement in QMS and implementation across different functions, incl. R&D, Quality and Technical operations
- On going digitization. LIMS implemented Unit-04 and is planned for rollout across additional sites

FDA Last US FDA inspection				
Key Facilities	Key Regulatory Certifications	Date	# audits (since inception)	EIR Status
Kilo Lab – R&D	USFDA, TGA, KFDA, PMDA, ANVISA - Brazil	2024	5	✓
Unit 1	USFDA, TGA, MHRA, WHO-Geneva, PMDA, ANVISA	2024	7	✓
Unit 2	USFDA, WHO-Geneva, EMA	2023	5	✓
Unit 3	USFDA, WHO-Geneva, JAZMP-Slovenia, ANVISA	2024	5	✓
Unit 4	WHO-Geneva, USFDA	2025	2	✓
Unit 5	USFDA	2022	1	✓
Unit 6	USFDA	2018	1	✓

Earnings call details

Laurus Labs Results Conference Call to be held on Thursday, 29 October 2026 at 5:00 PM IST

Dial – In – Details	
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 1012045
Hong Kong	+800 964448
USA	+1 866 746 2133
UK	+0808 101 1573

Click below to Express Join with
Diamond Pass

[Click here to register](#)

Additional Information

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions. The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its “Smart and Green” chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a “BBB” MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices. Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle “Chemistry for Better Living,” Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

Investor relations

Vivek Kumar

T: +914066594366

E: investorrelations@lauruslabs.com

E: vivek.k@lauruslabs.com

For more information

Please visit our website www.lauruslabs.com



Please consider the environment before printing this Presentation